INCY vs STE: fair value comparison
Incyte Corporation and STERIS plc · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, STE currently sits closer to the top of our discount ranking.
| INCY | STE | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $126.75 | $224.59 |
| 12-month range | $93.48–$125.01 | $211.07–$264.24 |
| Sector rank | #37 of 113 Healthcare | #33 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | — | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: INCY fair value analysis · STE fair value analysis